NCT03393468View on ClinicalTrials.gov

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 10, 2018

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions
HIV Infections
Interventions
DRUG

Dapivirine gel

Dapivirine gel (0.05%); administered rectally

Trial Locations (1)

15213

University of Pittsburgh CRS, Pittsburgh

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03393468 - Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults | Biotech Hunter | Biotech Hunter